These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28603138)

  • 1. Single-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes.
    Tschöp M; DiMarchi R
    Diabetes; 2017 Jul; 66(7):1766-1769. PubMed ID: 28603138
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimization of peptide-based polyagonists for treatment of diabetes and obesity.
    Knerr PJ; Finan B; Gelfanov V; Perez-Tilve D; Tschöp MH; DiMarchi RD
    Bioorg Med Chem; 2018 Jun; 26(10):2873-2881. PubMed ID: 29153547
    [No Abstract]   [Full Text] [Related]  

  • 3. Moving towards a more precise treatment of diabetes.
    Gruber K
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):171. PubMed ID: 25702247
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.
    Sadry SA; Drucker DJ
    Nat Rev Endocrinol; 2013 Jul; 9(7):425-33. PubMed ID: 23478327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
    McIntosh CH; Demuth HU; Kim SJ; Pospisilik JA; Pederson RA
    Int J Biochem Cell Biol; 2006; 38(5-6):860-72. PubMed ID: 16442340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon.
    Sekar R; Singh K; Arokiaraj AW; Chow BK
    Int Rev Cell Mol Biol; 2016; 326():279-341. PubMed ID: 27572131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glucagon-like peptide-1 on the beta cell response to glucose-dependent insulinotropic polypeptide in elderly patients with diabetes mellitus.
    Meneilly GS; Elahi D
    J Am Geriatr Soc; 2006 Mar; 54(3):554-5. PubMed ID: 16551338
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
    Ortúzar N
    ChemMedChem; 2013 Apr; 8(4):535-7. PubMed ID: 23529925
    [No Abstract]   [Full Text] [Related]  

  • 10. Mono-ADP-ribosyltransferase as a potential pharmacological drug target in the GLP-1 based therapy of obesity and diabetes mellitus type 2.
    Bavec A
    Acta Chim Slov; 2013; 60(2):237-42. PubMed ID: 23878926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].
    Spasov AA; Chepljaeva NI
    Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery.
    Patriti A; Facchiano E; Sanna A; Gullà N; Donini A
    Obes Surg; 2004; 14(6):840-8. PubMed ID: 15318993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus.
    Clements RH; Gonzalez QH; Long CI; Wittert G; Laws HL
    Am Surg; 2004 Jan; 70(1):1-4; discussion 4-5. PubMed ID: 14964537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamic incretin adaptation and type 2 diabetes.
    Ahrén B
    J Clin Endocrinol Metab; 2011 Mar; 96(3):620-2. PubMed ID: 21378226
    [No Abstract]   [Full Text] [Related]  

  • 15. The future of diabetes treatment.
    Petersen JS
    Ann Endocrinol (Paris); 2008 Apr; 69(2):166-7. PubMed ID: 18440491
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
    Stafford S; Elahi D; Meneilly GS
    J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
    [No Abstract]   [Full Text] [Related]  

  • 17. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
    Kluz J; Adamiec R
    Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.
    Mayfield K; Siskind D; Winckel K; Russell AW; Kisely S; Smith G; Hollingworth S
    J Psychopharmacol; 2016 Mar; 30(3):227-36. PubMed ID: 26801056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretins, diabetes, and bariatric surgery: a review.
    Fetner R; McGinty J; Russell C; Pi-Sunyer FX; Laferrère B
    Surg Obes Relat Dis; 2005; 1(6):589-97; discussion 597-8. PubMed ID: 16925299
    [No Abstract]   [Full Text] [Related]  

  • 20. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.